Abstract: Recombinant fusion proteins are an expanding, important class of novel therapeutic agents. The designs of these constructs typically involve a cell-targeting motif genetically fused to a highly toxic class of enzymes capable of ruthlessly attacking critical cellular machinery once delivered successfully to the cytoplasm of the target cell. Initial development of this class of constructs typically contained recombinant growth factors or single-chain antibodies as the celltargeting motif fused to highly cytotoxic plant or bacterial toxins. This review describes second-generation molecules composed of cell-targeting molecules fused to highly cytotoxic human enzymes capable of generating intense apoptotic response once delivered to the cytoplasm. The human serine protease granzyme B has been shown to be extremely effective as a cytotoxic molecule when incorporated into numerous cell-targeting constructs. The biological activity of GrBcontaining constructs rivals that of plant or bacterial toxins and appears to represent a new generation and class of completely human proteins with unique biological activities.
INTRODUCTION
The successful development of targeted therapeutics for cancer applications depends on the identification of ligands and antigens specific for tumor cells (or their microenvironment), generation of molecules capable of targeting those components specifically after systemic administration and, finally, delivery of highly toxic molecules to the tumor (or its surroundings). Immunoconjugates composed of antibodies and small, toxic drugs or radioisotopes have been successfully tested in vitro, in animal models and have demonstrated activity in the clinical setting. This field has been the subject of numerous excellent reviews [1] [2] [3] [4] [5] [6] [7] .
In addition to the use of small molecules for the toxin component, a number of groups have utilized highly cytotoxic protein toxins such as diphtheria toxin, ricin A-chain, Pseudomonas exotoxin, gelonin (rGel) in addition to others [8] [9] [10] [11] [12] [13] [14] [15] [16] . However, problems such as capillary leak syndrome, immunogenicity and toxicity continue to limit enthusiasm for long-term or chronic applications of these agents in the cancer setting. Studies by Pastan et al. [17] have demonstrated engineered toxin analogs of Pseudomonas exotoxin with reduced antigenicity compared to the original molecule. Studies in our laboratory have also demonstrated rGel analogs with reduced antigenicity and size [18] although immunotoxins containing rGel have demonstrated a low degree of immunogenicity in the clinical setting [19] even after repeated administration. Although there are a number of exquisitely cytotoxic payloads as mentioned above which are available for the construction of targeted therapeutic agents, there are a number of considerations which are relevant to the identification of molecules which constitute a class of "perfect" protein payloads. One of the first characteristics we considered was that the payload should be a relatively small human protein in the size range of the current toxins (approximately 25 kDa) or smaller if possible. In addition, this payload should not have a nominal cell-binding and internalization route or at least should have a cell-binding component, which can be engineered out of the molecule. Another characteristic would be that the molecule should be an enzyme, which acts, in a multi-component cellular cascade to reduce the possibility of developing cellular resistance to the delivered therapeutic agent. Finally, the cellular pathways necessary for cellular cytotoxic effects would have to be present in all cells and, in particular, all cancer cells.
DRUG TARGETING SYSTEMS
There are a large number of molecules which potentially fit the considerations mentioned above including several kinases, phosphatases, nucleases [20] [21] [22] [23] and proteases [24] [25] [26] . One candidate molecule we identified involves the granule-associated serine proteases called granzymes. The serine protease granzyme B (GrB) is integrally involved in apoptotic cell death induced in target cells upon their exposure to cytotoxic T-lymphocytes (CTL) and natural killer (NK) cells (Fig. (1) ).
The granule secretion pathway appears to require the direct intracellular delivery of this family of proteases (granzyme A and GrB), that activate both caspase-independent and -dependent death programs to ensure that the targeted cell dies [27] [28] [29] . Perforin, well known for its pore-forming capacity, has long been considered the vehicle that provides the gateway for entry of granzymes through the plasma membrane [30] [31] [32] . In CTL-mediated cytolysis, perforin is initially inserted into the target cell membranes and polymerizes to form transmembrane pores which facilitates access of NK or CTL-released GrB to the target cell cytoplasm. GrB appears to have the most potent apoptotic activity of all granzymes, as a result of its caspase-like ability to cleave substrates at key aspartic acid residues. The cell deathinducing properties of GrB have recently been studied in detail [33] [34] [35] [36] [37] . GrB can cleave and directly activate several procaspases, and it can also directly cleave downstream caspase substrates such as the inhibitor of caspase-activated DNase [38] . Although many procaspases are efficiently cleaved in vitro, GrB-induced caspase activation occurs in a hierarchical manner in intact cells, commencing at the level of "executioner caspases" such as caspase-3, followed by caspase-7 [39] . Overexpression of the anti-apoptotic Bcl-2 protein in mitochondria inhibits GrB completely, indicating that mitochondrial disruption is an indispensable feature of granzyme-mediated cell death [40] . In addition to caspasedependent mechanisms, there are also caspase-independent pathways: cells in which caspase activity is blocked can also be killed by granzymes, although the caspase-independent mechanisms are poorly understood [41] . In addition to the caspase-mediated cytotoxic events, GrB can also rapidly translocate to the nucleus and cleave poly (ADP-ribose) polymerase and nuclear matrix antigen, utilizing different cleavage sites than those preferred by caspases [42, 43] . In addition, some studies have shown that GrB can direct damage to non-nuclear structures such as mitochondria, subsequently induce cell death through caspase-independent pathways [44] [45] [46] .
Since almost all cells contain mechanisms responsible for mediating cell death (apoptosis) we propose that targeted delivery of GrB to the interior of cells will result in cell death through apoptotic mechanisms assuming that sufficient quantities of active enzyme can be successfully delivered to the appropriate subcellular compartment (Fig. (2) ).
In addition to providing a cytotoxic insult directly to target cells, an additional aspect of delivering pro-apoptotic agents is the potential for impacting radio-sensitivity, metastatic spread and sensitivity to chemotherapeutic agents. Numerous studies have suggested that the apoptotic status of cells impacts all three phenomenon and an additional rationale for targeting pro-apoptotic agents is the potential for impacting these cellular events in a unique fashion.
The rationale described above was the impetus for our original studies focusing on developing targeted therapeutic agents targeting tumor vasculature by using vascular endothelial growth factor-A (VEGF) and melanoma-associated antigen gp240 by using the single chain Fv antibody scFvMEL.
GrB/scFvMEL FUSION CONSTRUCT
To target melanoma cells, we chose the recombinant single-chain antibody scFvMEL, which recognizes the highmolecular-weight glycoprotein gp240, found on a majority of melanoma cell lines and fresh tumor samples [47, 48] . Others and we have demonstrated that this antibody possesses high specificity for melanoma and is minimally reactive with a variety of normal tissues, making it a promising candidate for further study [49] [50] [51] [52] . In the present study, we used scFvMEL as a tumor cell-targeting carrier and designed a novel recombinant fusion construct designated GrB/ scFvMEL, containing human pro-apoptotic enzyme GrB (Fig. (3) ). The purpose of these studies was to determine whether an antibody delivery vehicle would be sufficient to deliver active GrB enzyme to drive cellular apoptotic events specifically in melanoma target cells.
The fusion protein was generated by PCR, sequenced and cloned into a bacterial expression system (pET-32, Novagen) containing a thioredoxin tag upstream of the coding sequence for the final protein. The material was purified from bacterial paste using immobilized metal affinity chromatography and the final product was generated by enterokinase cleavage to uncover the N-terminal Ile of the GrB molecule, which is essential for enzymatic activity [53] . An ELISA was performed to determine the binding specificity of the GrB/scFvMEL fusion construct to antigen-positive A375-M and to antigen negative SKBR3 cells. As shown in Fig. (4) , GrB/scFvMEL specifically bound to antigenpositive A375-M cells but we were able to detect little binding to antigen-negative SKBR3 cells. ELISA of GrB/scFvMEL on gp240 Ag-positive A375-M versus gp240 Ag-negative SKBR3 cells detected using an anti-GrB mAb. Ninety-six-well plates containing adherent A375-M or SKBR3 cells (5 x 104 cells/well) were blocked by addition of 5% BSA and then treated with purified GrB/scFvMEL at various concentrations. After washing, the cells were incubated first with anti-GrB mAb, and then with HRP-GAM. Then, substrate solution (ABTS plus 1 l/ml 30% H2O2) was added. A405 nm was measured after 30 min. To assess the functionality of the GrB component of the fusion construct, the ability of the enzyme to cleave a BAADT substrate was assessed and compared to a known GrB standard ( Table 1) . The fusion construct GrB/scFvMEL was shown to have intact GrB enzymatic activity with a specific activity comparable to that of the unmodified enzyme, (SA = 2.6 10 5 units/ mole for the GrB/scFvMEL compared to 4.8 10 5 units/ mole for native GrB). As expected, the fusion construct which had the thioredoxin tag on the molecule (non-rEK cut) had no activity since the N-terminal Ile of the GrB was hindered.
The GrB moiety of GrB/scFvMEL was delivered into the cytosol of A375-M cells after treatment with GrB/scFvMEL for 1 h or 6 h assessed by analysis of confocal microscope imaging as detected by anti-GrB antibody (Fig. (5) ). GrB was found in the cytosol after treatment for 1 h, and the signals were stronger after treatment for 6 h than that after 1 h demonstrating localization and concentration of the construct over time. Antibody ZME-018 is the parental murine antibody for the scFvMEL recombinant fragment. Both agents recognize the same antigenic domain on the gp240 target antigen present on the cell surface of human melanoma cells. When cells were pre-treated with ZME-018, GrB fluorescent signal could not be detected in the cytosol after treatment with the construct, demonstrating that the uptake of the construct is dependant on specific interaction with gp240 on the cell surface. Internalization of GrB/scFvMEL into A375-M cells assessed by confocal microscopy. A375-M cells were pretreated with ZME-018 (3 M) for 2 h, and the cells were then treated with 40 nM GrB/scFvMEL for 1 or 6 h. Molecules bound to the cell surface were removed by brief treatment with glycine buffer (pH 2.5). Cells were fixed in 3.7% formaldehyde and permeabilized in 0.2% Triton X-100. Samples were blocked with 3% BSA, incubated with goat anti-GrB mAb, and then incubated with FITC-coupled anti-goat IgG and PI. The slides were mounted with DABCO containing 1 g/ml of PI and analyzed by Zeiss LSM 510 confocal laser scanning microscopy. A, no GrB/scFvMEL treatment control. B, pretreatment with ZME-018 (3 M), then GrB/scFvMEL treatment for 1 h. C, pretreatment with ZME-018, then GrB/scFvMEL treatment for 6 h. D, GrB/scFvMEL treatment for 1 h. E, GrB/scFvMEL treatment for 6 h. Cytotoxicity of the GrB/scFvMEL fusion toxin on A375-M and SKBR3. Log-phase cells were plated into 96-well plates at a density of 2.5 x 103 cells per well and allowed to attach for 24 h. The medium was replaced with medium containing different concentrations of GrB/scFvMEL. After 72 h, the effect of fusion toxin on the growth of cells in culture was determined using crystal violet staining. The IC50 of GrB/scFvMEL was 20 nM on A375-M cells. In contrast, no cytotoxicity was observed on SKBR3 cells.
The cytotoxicity of GrB/scFvMEL was next assessed against log-phase A375-M and SKBR3 cells in culture. A 50% growth inhibitory effect was found at a concentration of ~20 nM on A375-M cells. However, no cytotoxic effects were found on SKBR3 cells at doses of up to 1 M (Fig.  (6) ). By comparison, the cytotoxic effects of GrB/scFvMEL were approximately the same as that of another fusion toxin, scFvMEL/rGel on A375-M (Fig. (7) ). When A375-M cells were pre-treated with ZME-018 (40 mg/mL) for 6 h and then treated with GrB/scFvMEL for 72 h, the cytotoxicity of GrB/scFvMEL was abolished (Fig. (7) ) thereby demonstrating a requirement for antigen recognition in the cytotoxic effect of the GrB/scFvMEL fusion construct. In addition, we examined the cytotoxic effects of GrB/scFvMEL construct still containing the thioredoxin tag and therefore containing GrB, which was enzymatically inactive. As shown in Fig.  (7) , this molecule demonstrated no cytotoxic effects at the highest doses tested. This demonstrates that the enzymatic activity of the GrB molecule is essential for generating the cytotoxic effect.
Both antigen-positive and antigen-negative cells were treated with an IC 50 concentration of the GrB/scFvMEL fusion construct. At various times (0, 8 and 16 h) after administration, the cells were stained for apoptosis using the TdT-mediated dUTP-biotin nick end labeling (TUNEL) assay. Apoptotic cells were shown up at 8 h treatment. Within 16 h after administration, virtually all antigenpositive cells were positive for apoptosis (Fig. (8) ). In contrast, there was no apoptosis found in non-target cells treated with identical doses of the fusion construct.
As demonstrated in Fig. (9) , treatment with GrB/scFvMEL induced caspase 3 cleavage on antigen-positive A375-M cells but not on antigen-negative SKBR3 cells after treatment for 4 h. Moreover, cytochrome c was released from mitochondria into the cytosol on A375-M but not on SKBR3 cells after treatment with GrB/scFvMEL at 50 nM for 16 h (Fig.  (9) ). Comparative cytotoxicity of GrB/scFvMEL and MEL sFv/rGel and effect of addition of ZME-018 on cytotoxicity of GrB/scFvMEL against A375-M cells. Log-phase A375-M cells were plated into 96-well plates (2.5 x 103 cells per well) and allowed to attach for 24 h. The medium was replaced with medium containing different concentrations of GrB/scFvMEL or MEL sFv/rGel. Cells were also pretreated with ZME-018 (40 mg/ ml) for 6 h and then co-treated with various concentrations of GrB/scFvMEL. After 72 h, the cells were stained with crystal violet. Plates were read on a microplate ELISA reader at 595 nm. The IC50 of GrB/scFvMEL was approximately identical to that of MEL sFv/rGel on A375-M. ZME-018 pretreatment inhibited the cytotoxicity of GrB/scFvMEL on A375-M cells.
Finally, we generated large amounts of purified, endotoxin free fusion protein and administered the construct (or saline) to groups of 8 mice (by iv administration) bearing well-developed A-375 tumors growing subcutaneously. We used a QOD X5 schedule and as shown in Fig. (10) , tumors from control mice increased from 50-1200 mm 3 while the tumors in the treated group increased to 200 mm 3 . There was a long-term inhibitory effect noted since tumors from the treated group remained static.
Bearing A375 Xenografts
These preliminary mouse experiments clearly demonstrated the in vivo potential of constructs targeting tumor cells and containing GrB. The doses used showed no obvious toxicity and were likely well below the maximum tolerated dose. In vivo efficacy, pharmacokinetics and tissue disposition studies are continuing.
GrB FUSED TO VEGF 121 (GrB/VEGF 121 )
Various soluble cytokines have been shown to mediate angiogenesis in vitro and in vivo [54, 55] . VEGF plays a central role in both normal vascular tissue development and in A. GrB/scFvMEL induced caspase-3 cleavage on antigen-positive A375-M. A375-M and SKBR3 cells (2 x 105) were treated with GrB/scFvMEL at 50 nM for various times (2, 4, 8, and 16 h). Whole cell lysate (30 g) was analyzed by 12% SDS-PAGE and followed by immunoblotting to detect caspase-3 or cleaved caspase-3. Pro-caspase-3 was cleaved into one fragment at 4 h and further cleaved into smaller fragments after treatment for 8 h by GrB/scFvMEL on A375-M cells. We found no caspase-3 cleavage on SKBR3 cells treated with GrB/scFvMEL.
B.
Cytochrome c released from mitochondria to cytosol by GrB/scFvMEL on A375-M. Cells (5 x 107) were treated with GrB/scFvMEL at 50 nM for various times (2, 4, 8, and 16 h). Cells were collected, and the cytosolic and mitochondrial fractions were isolated. Fractions (30 g) from nontreated and treated cells were analyzed by 15% SDS-PAGE and immunoblotting, detected with an anti-cytochrome c antibody. Cytochrome c was found to be released on A375-M cells but not on SKBR3 cells after 4 h treatment by GrB/scFvMEL. tumor neovascularization [56] [57] [58] . The lowest molecular weight isoform of VEGF, VEGF 121, is a soluble, nonheparin-binding variant that exists in solution as a disulfidelinked homodimer. VEGF 121 has been demonstrated in previous studies to contain the full biological activity of the larger variants [59, 60] . The angiogenic actions of VEGF are mediated via two closely related endothelium-specific receptor tyrosine kinases, the human VEGF receptor 1 (fmsrelated tyrosin kinase-1 (FLT-1)) and VEGF receptor 2 (kinase insert domain receptor (KDR) or fetal liver kinase-1 (FLK-1) ). Both are largely restricted to vascular endothelial cells [61] [62] [63] [64] .
We previously selected VEGF 121 for our studies because we consider it an appropriate carrier to deliver toxic agents to tumor endothelial cells that overexpress the KDR/FLK-1 receptors. Recently, we described a fusion toxin composed of VEGF 121 and the recombinant plant toxin rGel [65] . This construct was shown to be selectively cytotoxic to vascular endothelial cells overexpressing the KDR/FLK-1 receptor for VEGF in both in vitro and xenograft models. We demonstrated that VEGF 121 ligand is an excellent delivery platform with which to target tumor vascular endothelium cells in vivo in PC-3 tumor xenografts. In addition, studies against numerous tumor xenograft models demonstrated impressive activity as a single agent [66, 67] . Finally, we found that both VEGF 121 itself and fusion constructs containing VEGF 121 were capable of providing excellent imaging information for solid tumors [68] as a potential predictor of response to targeted therapeutics using VEGF 121 . In addition, we found these fusion constructs demonstrated exceptional activity as therapeutics against non-tumor applications such as ocular neovascularization [69] .
The GrB/VEGF 121 construct (Fig. (11) ) was one of the first we described in a paper originally published in Molecular Cancer Therapeutics [70] .
The fusion construct GrB-VEGF 121 was composed of GrB engineered to contain an enterokinase cleavage site upstream of the GrB protein so that enterokinase digestion would leave an isoleucine residue as the N-terminal amino acid of the GrB protein. In its natural activation process inside cytotoxic cells, active GrB is generated from a zymogen by the action of dipeptidyl peptidase I-mediated proteolysis [71] , which removes the two residue (Gly Glu) propeptide and exposes Ile-21. The N-terminal Ile-Ile-Gly-Gly sequence of GrB is necessary for the mature, active GrB. The GrB was fused to the VEGF 121 coding sequence tethered by a short, flexible G 4 S tether to relieve steric stress on both molecules.
The construct was cloned, sequenced and expressed in bacterial cells using the pET bacterial expression system (Novagen). Bacterial paste from a small-scale (5 L) fermentor was lysed and the soluble fraction was applied to immobilized metal affinity columns followed by imidazole elution, enterokinase digestion and final purification. Purity was assessed by SDS-PAGE and Western blot analysis. The dimeric nature of the complex was established by SDS-PAGE under reducing and non-reducing conditions. The purified GrB/VEGF 121 construct was then assessed against log-phase transfected porcine aortic endothelial (PAE) cells transfected with either KDR/FLK-1 or FLT-1 human receptors for VEGF. As shown, the construct was highly cytotoxic to cells expressing the KDR/FLK-1 receptor but were not cytotoxic to cells expressing the FLT-1 receptor. IC 50 values were found to be ~ 10 nM and were similar to the values obtained with the VEGF 121 /rGel fusion toxin against the same cell line (Fig. (12) ).
Clonogenic studies (Fig. (13) ) were performed against these same transfected PAE cells and IC 50 values obtained Fig. (11) . Schematic Representation of GrB/VEGF 121 .
for the GrB/VEGF 121 construct were similar to that found for log-phase culture (20 nM vs 10 nM respectively). Internalization studies were also performed. Transfected endothelial cells were treated for 4 h with the fusion construct and the cells were treated with a low pH wash to remove cell-surface bound material, fixed and immunostained for GrB. As shown in Fig. (14) , the construct rapidly internalized into cells expressing the FLK-1 receptor, but not in cells expressing the FLT-1 receptor. The observed specificity of VEGF 121 -related fusion constructs for targeting the FLK-1 receptor compared Fig. (12) . Cytotoxic effects of GrB/VEGF 121 on log-phase endothelial cells.
Cytotoxicity of the GrB/VEGF121 fusion toxin on transfected endothelial cells. XTT cytotoxicity assay. Log-phase PAE cells were plated into 96-well plates at a density of 2.5 x 103 cells/well and allowed to attach for 24 h. The medium was replaced with medium containing different concentrations of GrB/VEGF121. After 72 h, the effect of fusion toxin on the growth of cells in culture was determined using XTT. Plates were read on a microplate ELISA reader at 540 nm. IC50 of GrB/VEGF121 was 10 nM on PAE/FLK-1 cells; it was not cytotoxic on PAE/FLT-1 cells.
Fig. (13). Effects of various doses of GrB/VEGF 121 on clonality of endothelial cells.
Cologenic assay. 5 x 105 cells/ml were incubated at 37°C and 5% CO2 for 72 h with different concentrations of GrB/VEGF121 and 100 nM of irrelevant fusion protein GrB/scFvMEL. Cells were then washed with PBS, trypsinized, counted, and diluted serially. The serial cell suspensions were then plated in triplicate and cultured in six-well plates for 5-7 days. Cells were stained with crystal violet and colonies consisting of >20 cells were counted. Columns, percentage of colonies in relation to the number of colonies formed by untreated cells.
to the FLK-1 receptor had been observed originally with VEGF 121 /rGel [72] . We attributed this finding to the possibility that the FLK-1 receptor but not the FLT-1 receptor had a strong kinase activity, which may contribute to its internalizing characteristics. Subsequent studies in our group have demonstrated that FLT-1 receptors expressed on osteoclast progenitor cells appear to internalize well into cells and are capable of mediating selective sensitivity to VEGF-related fusion constructs.
We next examined the cytotoxic mechanism of GrB/ VEGF 121 action against target cells and related the effects to those known to be related to GrB activity. PAE cells were treated for various times with IC 50 doses of GrB/VEGF 121 construct and were stained for apoptosis via TUNEL staining. As shown in Fig. (15) (left) , within 24 h after administration of the agent, FLK-1-positive cells demonstrated intense apoptotic staining. Quantitative assessment (Fig. (15),   Fig. (14) . Rapid internalization of GrB/VEGF 121 on endothelial cells. PAE cells were plated onto 16-well chamber slides (1 x 104 cells/well). Cells were treated with 100 nM of GrB/VEGF121 for 4 h and then washed briefly with PBS. The cell surface was stripped with glycine buffer (pH 2.5) and the cells were fixed in 3.7% formaldehyde and permeabilized in PBS containing 0.2% Triton X-100. After blocking, samples were incubated with anti-GrB antibody and treated with FITCcoupled anti-mouse IgG. The slides were analyzed under a fluorescence microscope. The GrB moiety of GrB/VEGF121 is delivered into the cytosol of PAE/FLK-1 but not into that of PAE/FLT-1 after 4-h treatment. The pro-apoptotic effects of GrB/VEGF 121 were further confirmed by examining DNA degradation in transfected endothelial cells. As shown in Fig. (16) , the GrB fusion construct caused an impressive degradation of DNA in FLK-1-transfected cells but not in the FLT-1-transfected cells thus confirming our observation of specificity and activity of the fusion protein. Again, this is in sharp contrast to studies with VEGF 121 /rGel, which found specific cytotoxic effects of the construct but the activity appeared to be a necrotic damage rather than an apoptotic effect since we could find no evidence of DNA laddering, TUNEL positivity or caspase activation in treated cells (M.G. Rosenblum, et al. manuscript in preparation).
Fig. (16). DNA degradation specifically on FLK-1-transfected cells treated with GrB/VEGF 121
GrB/VEGF121 induces DNA laddering in PAE/FLK-1 cells. Cells were plated into six-well plates at a density of 2 x 105 cells/well and exposed to 20-nM GrB/VEGF121 for 24 h. DNA was isolated from cell lysates and fractionated on 1.5% agarose gel.
Further mechanistic studies were performed to evaluate the activation profile for intracellular caspase cascade, which is a well-described mechanism of GrB cytotoxic effect. PAE cells were treated with GrB/VEGF 121 , and total cell lysates were loaded onto 12% SDS-PAGE and standard Western blotting was performed. The results showed that treatment with GrB/VEGF 121 cleaved caspase-8, caspase-3, and PARP on PAE/FLK-1-transfected cells but not on PAE/FLT-1-transfected cells (Fig. (17) ). These data clearly indicate that the GrB/VEGF 121 construct acts through activation of caspases involved in the apoptosis pathway.
GrB-Ki4(scFv)
One of our first goals during the last decade was the development of recombinant immunotoxins for the treatment of Hodgkin's lymphoma [73] . Initially we developed our own bacterial vectors for periplasmic expression in E. coli [74] and a novel expression technology [75] . We subsequently used this for the generation of the first Pseudomonas exotoxin-based immunotoxins targeting cluster of differentiation (CD)30 overexpressed on Hodgkin-Reed/Sternberg cells [76] [77] [78] [79] . During this time we also used this expression system to develop the first human immunotoxins also targeting CD30 [80] . Fig. (17) . Caspase activation and PARP cleavage in cells treated with GrB/VEGF 121 Cleavage and activation of caspase-3, caspase-8, and PARP in PAE/FLK-1 cells. PAE cells were plated into six-well plates at a density of 2 x 105 cells/well and treated with 20-nM GrB/VEGF121 for 4 h. The total cell lysates were loaded onto 12% SDS-PAGE and Western blot was performed using appropriate primary antibodies.
Because some of the human enzymes including GrB could not be expressed in sufficient amounts in our bacterial expression system, we designed a new eukaryotic system for the transient expression of recombinant human immunotherapeutics [81] (Fig. (18) ).
Subsequently used this expression system to express GrB-based immunotoxins also targeting CD30. Specific binding of the first anti-CD30 GrB fusion protein (GrBKi4(scFv)) was documented by flow cytometry (Fig. (19) ).
As we thereby confirmed the expression of human immunotoxins in mammalian cells, we also covered the corresponding vectors for expression and gene therapeutic approaches for in vivo and ex vivo transfection of human producer cells in this granted patent.
GrB-H22(scFv)
By starting a tight collaboration with Jan GJ van de Winkel, we obtained access to a recombinant antibody fragment H22(scFv) targeting Fc-gamma receptor 1 (CD64). This receptor is for example upregulated in subtypes M4 and M5 of acute myeloid leukemia (AML) and represents a prime target for specific delivery of e.g. cytotoxic agents into these cancer cells. We thus fused H22(scFv) to human GrB (Fig. (21) ) to obtain the novel CD64-specific recombinant immunotoxin GrB-H22(scFv) [82] .
The recombinant immunotoxin was successfully expressed in human 293T cells, secreted and purified from cell culture supernatants. The purified protein bound specifically to CD64+ U937 cells. Despite linkage to the binding domain, the proteolytic activity of functional GrB-H22(scFv) was identical to that of free GrB (Fig. (22) ). Backbone of these plasmids is the pSecTag2 part between the bovine growth hormone poly-adenylation site (BGH) and the constitutive CMV-promoter (pCMV), which initiates the expression of the two different bicistronic mRNAs. The ampicillin resistance gene (AmpR) and the bacterial origin of replication (ColE1) were used for plasmid propagation in E. coli. The Zeocin resistance gene (ZeoR) under control of the SV40-promoter (pSV40) was used for the selection of transfected 293T-cells. The leaders used was mouse Igk-leader (Igk-L). The recombinant IT is fused to a Myc/His-Tag epitope (MH) at their 3' ends for detection and purification. They are followed by the pIRES-EGFPvector-derived synthetic intron (IVS), to stabilize the mRNA, and an internal ribosomal entry site (IRES), which enables the co-translation of the enhanced green fluorescent protein (EGFP).
Fig. (19). Flow cytometric (FACS) analyses of anti-CD30 GB supernatants.
FACS analyses were performed on CD30 + (L540Cy) and CD30 -cell lines (IMR5). No staining was observed on the negative cells and controls. In contrast, the staining of the CD30 + cells with the anti-CD30 GB was identical with that of the positive control with Ki4moAb (not shown).
Target cell specific cytotoxicity was observed with a half maximal inhibitory concentration (IC 50 ) between 1.7 and 17 nM. Induction of apoptosis was also observed after application of GB-H22(scFv) to primary CD64+ AML cells, whereas CD64-AML cells were unaffected.
There have been several other groups, which have subsequently demonstrated the activity of granzyme-based fusion constructs. Kurschus et al. [83] generated a highly potent construct of GrB fused to a single-chain antibody targeting the Lewis-Y antigen. These constructs were highly cytotoxic to target cells displaying an excellent differential effect vs antigen-negative cells. Studies by Zhao et al. [84] [85] [86] have additionally demonstrated excellent cytotoxic effects using single-chain anti-HER2 antibodies fused to granzyme B. Finally, Dalken et al. [87] have generated numerous chimeric constructs targeting tumor cells and containing recombinant GrB. These studies demonstrate the potential universality of this approach for a number of applications.
CONCLUSIONS AND OUTLOOK
The studies described above appear to be among the first descriptions of the use of the pro-apoptotic, serine protease GrB in targeted therapeutic constructs. This agent is the culmination of our search for a human therapeutic protein that is both highly active and potentially universal. The studies described above have demonstrated that apoptosis induced by cellular delivery of GrB is characteristically a rapid process taking approximately 1 h to generate the hallmarks of apoptosis such as DNA fragmentation, caspase cleavage and cytochrome c release [88] . However, our Fig 18) .
Fig. (21). GB-H22(scFv) expression cassette in pMS (
GB was linked via its C-terminus to H22(scFv). The Ig kappa leader sequence (Ig l) preceding Gb facilitates secretion of the protein into the cell culture supernatant. An enterokinase cleavage site (ECS) allows the free Gb N-terminus to be regenerated in the cytosol. A C-terminal 6x-histidine tag (His 6 ) facilitates purification via IMAC. A synthetic intron sequence and an internal ribosome entry site followed by the gene coding enhanced green-fluorescent protein (eGFP) allow for co-expression of eGFP via a bicistronic mRNA and thus permit the detection of transfected 293T cells under a fluorescence microscope. 
CD64
+ U937 cells were incubated with increasing concentrations of Gb-H22(scFv) for 72 h in a humidified 37°C/5% CO 2 atmosphere. Cell viability in relation to a 100% PBS plus Enterokinase (EK) buffer (filled squares) and 100% PBS plus EK buffer plus Enterokinase control (filled circles) was determined with a colorimetric XTT-based cell viability assay. GB-H22 showed increased toxicity in comparison to EGB-H22 (not cleaved by Enterokinase). Samples were measured in triplicate wells. Error bars represent SD. studies indicated that these apoptotic events happened within approximately 8 h after treatment with fusion constructs containing GrB. We believe that this delay is likely due to the antibody internalization process or ligand-directed internalization process, which may require several hours for optimal delivery of the GrB to the cytosol. In any event, these studies clearly demonstrate that cell-targeting constructs are capable of specific delivery of GrB to the cytoplasm in quantities sufficient to overcome normal homeostasis and to drive cells into apoptosis. In addition, as a critical consideration, others and we have clearly demonstrated that the GrB enzyme was effective even while it remained covalently attached to an assembled targeting vehicle. This advance avoids problems with linker technology that can result in premature release of the active component prior to target internalization or loss of biological activity of the active component due to permanent attachment to the targeting molecule. Importantly, the demonstration of biological activity with a GrB-containing fusion protein does not appear to be confined to the current approach using VEGF 121 or single-chain antibodies as vehicles to target tumor endothelium or tumor cells themselves. Recent studies in our laboratory and by others have demonstrated impressive cytotoxic activity of GrB-containing fusion constructs composed of single-chain antibodies and other ligands targeting numerous human tumor cell types. The unique mechanism of action of GrB-based targeted therapeutic agents may also provide for novel interactions with other types of therapeutic agents or with other modalities such as chemotherapy, biological therapy, hyperthermia or radiation therapy. Further in vitro and animal studies with this agent are clearly warranted which will likely pave the way for clinical trials with agents containing GrB as the cytotoxic payload.
A discussion of the potential of GrB-based therapeutic agents would not be complete without a discussion of the potential for development of resistance to the cytotoxic properties of granzyme B itself. The intracellular serpin proteinase inhibitor, clade B, member 9 (SERPINB9) is the only known human protein that specifically inhibits GrB [89, 90] . The in vivo distribution of SERPINB9 suggests that this enzyme protects against unwanted GrB-mediated cytotoxicity. SERPINB9 was found to be expressed at immune-privileged sites and by endothelial, dendritic, and mesothelial cells, malignant lymphomas [91, 92] and estrogen receptor-positive tumors [93, 94] . Ex vivo experiments using NK cell lines and peripheral blood cells from healthy volunteers have provided evidence for subcellular localization and up-regulation of SERPINB9 during maturation of accessory cells and degranulation of effector cells [95] . In such systems, SER-PINB9 could associate with GrB-containing granules and form intracellular complexes, leading to inactivation of cytoplasmic GrB by SERPINB9. Godal et al. [96] found expression of SERPINB9 in 10 of 18 lymphoma cell lines and 9 of 14 primary lymphomas and all being sensitive to perforindependant cytolysis by specific T cells and cytokineactivated NK cells. In perforin-dependent pathways, GrB is the only known human granzyme that triggers cell death via the activation of caspases. The authors also found CTLinduced activation of caspases in SERPINB9-positive lymphoma cells indicating that the level of SERPINB9 expression was not sufficient to completely block GrB.
Therefore, for many of the constructs described in our studies, delivery of GrB using targeted therapeutic constructs may overwhelm the endogenous expression of natural inhibitors such as SERPINB9. Whether selection for SERPINB9 overexpressing cells presents a potentially important resistance mechanism for these therapeutic agents remains to be determined.
Finally, having shown the specific cytotoxicity of these GrB-based human immunotoxins, ongoing studies aim to develop human enzymes as novel immunotherapeutic agents for the future. The ultimate objective is the application of tailor-made immunotoxins not only in terms of the targeting component, but also the cytotoxic agents, which will be chosen specifically to destroy tumor cells, modify their cellular signaling properties, impact their ability to form viable metastatic lesions, reduce their ability to resist chemotherapeutic, radiotherapeutic or biological agents.
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